ArticleDrug design, development and therapy2026
Effect of Dosage Forms on the Steady-State Dose-Corrected Plasma Concentrations of Quetiapine and N-Desalkylquetiapine.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to determine the effects of dosage forms on the steady-state dose-corrected (C/D) concentrations of quetiapine and N-desalkylquetiapine in patients. Methods: This was a retrospective cohort study that included 831 therapeutic drug monitoring samples derived from 512 patients. Multiple linear regression analysis was used to identify independent factors that affected the C/D values for quetiapine and N-desalkylquetiapine. Moreover, we compared the C/D values of quetiapine and N-desalkylquetiapine between the two groups and conducted subgroup analyses based on daily dose, sex, and age. Results: The C/D ratio of quetiapine in the extended-release (XR) group was 1.7-fold higher compared with that in the immediate-release (IR) group ( Conclusion: Dosage form significantly affects the steady-state C/D ratio of quetiapine; however, it does not significantly affect the C/D ratio of N-desalkylquetiapine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.